News

BioM's articles and press releases about the Bavarian biotechnology sector


ITOC in Munich: 11th Immunotherapy of Cancer Conference

The Im­mun­o­ther­apy of Can­cer Con­fer­ence (ITOC) is a European meet­ing provid­ing a glob­al plat­form for trans­la­tion­al re­search in…

Nordic Life Science Days 2025: Discounted participation in the German Pavilion!

Nord­ic Life Science Days (NLS Days) is the lead­ing part­ner­ing and in­vestor con­fer­ence for the life sci­ence in­dustry in North­ern…

BIO-Europe 2025: Secure your spot at the German Pavilion!

BIO-Europe will take place from 3 – 5 Novem­ber 2025 in Vi­enna (Aus­tria). As the lead­ing part­ner­ing con­fer­ence in Europe, BIO-Europe…

Helmholtz invests 18 million Euros in AI innovation ecosystems

The new ‘HPC Gate­way’ ini­ti­at­ive aims to open up ac­cess to the Helm­holtz As­so­ci­ation's world-lead­ing HPC in­fra­struc­ture for…

“KHAN-II”: 51 million Euro for early-stage drug discovery investments

Khanu Fonds­ver­wal­tung GmbH (Khanu), a fund man­age­ment team from Dort­mund, Ger­many, fo­cus­ing on drug dis­cov­ery, an­nounces the…

Cardior co-founder and RNA expert Prof. Thomas Thum joins board of MAxL team RNATICS

Bi­otech start-up RNATICS strengthens its man­age­ment team with Prof. Dr. Tho­mas Thum. As an in­ter­na­tion­ally re­cog­nized ex­pert in…

Avelios Medical secures 30 million euros for hospital information system

The Mu­nich-based healthtech start-up Avelios Med­ic­al has raised 30 mil­lion euros in a Ser­ies A fin­an­cing round. The fin­an­cing round…

DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases

DEBRA Re­search GmbH, a non-profit or­gan­iz­a­tion loc­ated in Mu­nich ded­ic­ated to ad­van­cing re­search, ad­vocacy, and sup­port for…

Swiss Biotech Day 2025: Get your discounted ticket now!

The Swiss Bi­otech Day will again take place from 05 to 06 May 2025 in Basel (Switzer­land). The SBD has be­come one of the key events in…

m4 Award winner Tubulis starts clinical trial with ADC TUB-030 for the treatment of solid tumours

The Martin­sried-based bi­otech com­pany Tubulis has dosed the first pa­tient in its Phase I/IIa study in­vest­ig­at­ing the an­ti­body drug…